Compare Danaos Corporation (DAC) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Johnson & Johnson — how do they compare? Danaos Corporation trades at $169.09 (market cap $3.10B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 199.4× Danaos Corporation's market cap, and Danaos Corporation pays the higher dividend (2.35%). Which is the better fit depends on your goals — on Pluang, investors hold Danaos Corporation for 25 Days and Johnson & Johnson for 129 Days on average.
| DAC | JNJ | |
|---|---|---|
Market Cap | $3.10B | $618.09B |
Volume | 286,008 | 6,050,983 |
Sector | Industrials | Health |
52-Week High | $170.22 | $278.43 |
52-Week Low | $84.05 | $186.00 |
Typical Hold Time | 25 Days | 129 Days |
Enterprise Value | $3.08B | $646.37B |
Dividend Yield | 2.35% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DAC trades at $169.09, up 2.8% today, with a bullish technical signal and strong fundamental metrics. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $7.29 exceeding the $6.80 estimate. Valuation ratios are attractive, including a P/E of 5.76 and P/B of 0.76, while profitability remains high with a net income margin of 51.26%. Recent news highlights dividend declarations and institutional investment interest.
The outlook is positive given earnings momentum and shareholder returns via dividends, but risks include shipping market volatility and reliance on global trade flows. Analyst consensus is evenly split between Buy and Hold ratings, suggesting cautious optimism amid strong operational performance.
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
